THERMO FISHER SCIENTIFIC INC. Q4 FY2024 earnings call

Management Statement and Operational Highlights

• High-Impact Innovation: 2024 saw outstanding product launches across businesses, including mass spectrometers, ion chromatography systems, electron microscopes, and bio-based films for single-use technologies. Q4 continued innovation with new ICP-MS and Dynabeads platform additions.
• Commercial Engine and Trusted Partner Status: Strengthened commercial capabilities, expanded pharma services and clinical research, and launched Accelerator Drug Development solution to enhance drug development efficiency. Partnerships with NCI, FDA approvals, and university collaborations highlighted deepened customer relationships.
• PPI Business System: Enabled execution, driving share gain, quality, productivity, and customer allegiance, with generative AI application enhancing customer experience and processes.
• Corporate Social Responsibility: Progress on Net Zero roadmap, collaborations for health outcomes, and STEM education programs reaching over 180,000 students globally.

Segment Performance

• Life Sciences Solutions: Q4 reported revenue grew 5% with 3% organic growth; full year reported revenue declined 3% with 4% organic decline. Q4 adjusted operating income increased 6% with a margin of 36.6%, while full year adjusted operating income increased 2% with a margin of 36.4%.
• Analytical Instruments: Q4 reported revenue grew 7% with 8% organic growth; full year both reported and organic revenue grew 3%. Q4 adjusted operating income increased 13% with a margin of 30.5%, while full year adjusted operating income increased 2% with a margin of 26.2%.
• Specialty Diagnostics: Q4 reported and organic revenue grew 5%; full year reported revenue increased 2% with 3% organic growth. Q4 adjusted operating income increased 3% with a margin of 23.6%, while full year adjusted operating income was 3% higher with a margin of 25.7%.
• Laboratory Products and Biopharma Services: Q4 reported and organic revenue grew 4%; full year reported revenue grew 1% with organic flat. Q4 adjusted operating income increased 3% with a margin of 14%, while full year adjusted operating income declined 8% with a margin of 13.3%.

Guidance

• 2025 revenue guidance: $43.5 billion to $44 billion, assuming 3%-4% organic growth.
• Adjusted EPS guidance: $23.10 to $23.50, representing 6%-8% growth in adjusted earnings per share.
• Assumptions include 1% headwind from remaining pandemic-related revenue runoff, 1.5% revenue headwind from foreign exchange, and approximately 90 basis points of adjusted operating margin expansion.

Risks

• General market uncertainties and policy changes, including potential impacts from tariffs, NIH funding, and export controls, though the company aims to navigate such factors.

Question and Answer

• Q: Michael Ryskin from Bank of America asked about policy changes and EPS guide A: Marc Casper and Stephen Williamson discussed that guidance is built assuming market conditions will strengthen, with 6%-8% adjusted EPS growth expected, and they will navigate policy changes as they arise.
• Q: Rachel Vatnsdal from JPMorgan asked about Analytical Instrumentation and China stimulus A: Marc Casper noted strong innovation driving Analytical Instruments growth, with China showing revenue and order strength, and assumptions for China stimulus embedded in guidance.
• Q: Jack Meehan from Nephron Research asked about 2026 guidance A: Stephen Williamson and Marc Casper discussed confidence in returning to long-term growth rates, with 2025 guidance setting up for future success, though 2026 specifics were not detailed.
• Q: Doug Schenkel from Wolfe Research asked about top line and margin expansion A: Marc Casper and Stephen Williamson explained that margin expansion is driven by PPI Business System execution, cost discipline, and focus on driving revenue to bottom line, with confidence in continuing such performance in future years.
• Q: Tycho Peterson from Jefferies asked about accelerator program and China A: Marc Casper discussed strong interest in the Accelerator Drug Development solution, with momentum in biotech and large pharma, and China assumptions based on muted environment and small impact from value-based procurement.
• Q: Puneet Souda from Leerink Partners asked about biopharma customers and China's drug discovery A: Marc Casper noted positive confidence from large pharma and emerging biotechs, with Thermo Fisher positioned well globally, including in China, due to innovation and customer partnerships.